-
Mashup Score: 18
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is a heterogenous condition encompassing multiple subtypes with varying histopathology, prognosis, and potential treatment options. The most common RA-ILD subtypes are usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP). RA-UIP is characterized by fibrosis and portends the worst prognosis but may be treated with antifibrotic therapy. RA-NSIP is […]
Source: acrabstracts.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 27
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is a heterogenous condition encompassing multiple subtypes with varying histopathology, prognosis, and potential treatment options. The most common RA-ILD subtypes are usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP). RA-UIP is characterized by fibrosis and portends the worst prognosis but may be treated with antifibrotic therapy. RA-NSIP is […]
Source: acrabstracts.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 19
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Prior work suggests recent GC use is associated with major adverse cardiovascular events (MACE) in RA, but these studies did not adequately consider the effect of prior GC exposure on current risk. Methods: In this retrospective cohort study, we used national VA administrative […]
Source: acrabstracts.orgCategories: General Medicine News, RheumatologyTweet-
There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/VOUmsvAs2r https://t.co/LKtuuoD3xa
-
-
Mashup Score: 14
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Prior work suggests recent GC use is associated with major adverse cardiovascular events (MACE) in RA, but these studies did not adequately consider the effect of prior GC exposure on current risk. Methods: In this retrospective cohort study, we used national VA administrative […]
Source: acrabstracts.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 13
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Prior work suggests recent GC use is associated with major adverse cardiovascular events (MACE) in RA, but these studies did not adequately consider the effect of prior GC exposure on current risk. Methods: In this retrospective cohort study, we used national VA administrative […]
Source: acrabstracts.orgCategories: General Medicine News, General HCPsTweet-
There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/RdLUvW3W7v https://t.co/CcQXQYwu7J
-
-
Mashup Score: 6Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - ACR Meeting Abstracts - 5 month(s) ago
Background/Purpose: The current recommendations for the treatment of LN consider as the standard of care (SoC) the use of MMF or CYC. Considering the expanding evidence for the use of calcineurin inhibitors (CNI) in patients with LN, we aimed to summarize and assess the efficacy and safety of CNI compared to the current SoC for […]
Source: acrabstracts.orgCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1
Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting for weeks or longer in individuals who have recovered from SARS-CoV-2 infection. Symptoms include breathlessness, cough, chest tightness, palpitations, fatigue, myalgia, and difficulty concentrating. Estimates of 30% who contracted COVID-19 […]
Source: acrabstracts.orgCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 3
Background/Purpose: IL-17 inhibition demonstrates efficacy in multiple disease domains in psoriatic arthritis. Izokibep is a unique IL-17A inhibitor with high IL-17A binding affinity (KD= 0.3 pM), small molecular size (18.6 kDa), and an albumin attachment site. Week 16 data showed ACR50 of 52% and enthesitis resolution rates of 88%. We report data from baseline to […]
Source: acrabstracts.orgCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 2
Background/Purpose: PsA is characterized by inflammatory arthritis, enthesitis, dactylitis, and spondylitis. Apremilast (APR) is an oral immunomodulating phosphodiesterase-4 inhibitor approved for the treatment of PsA. Here, we evaluate the efficacy of APR 30 mg BID on inflammation measured by a dedicated MRI of the hand. Methods: MOSAIC (NCT03783026) was a phase 4, multicenter, single-arm, open-label […]
Source: acrabstracts.orgCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1
Background/Purpose: Individualized treatment strategies are of high importance in the treatment of patients with active psoriatic arthritis (PsA), a heterogeneous immune-mediated disease. IL-17 inhibition has demonstrated efficacy in all domains of PsA. Nevertheless, approx. 30% of patients will not achieve remission after initiation of therapy. Therefore, the identification of patient characteristics with a high impact […]
Source: acrabstracts.orgCategories: General Medicine News, RheumatologyTweet
Pearl: Three "S" Rule (Smoking, Seropositivity, Sex/Male): if present the risk of RA-UIP (ILD) goes up nearly 13 fold (ACR23 Abstract 1269) https://t.co/2YFosInpGs https://t.co/rOVN79JJRz